Arterial Blood, Rather Than Venous Blood, is a Better Source for Circulating Melanoma Cells

Overview

Journal EBioMedicine

Specialty Biomedical Engineering

Date 2016 Feb 13

PMID 26870807

Citations 30

Authors

Mizue Terai

Zhaomei Mu

David J Eschelman

Carin F Gonsalves

Ken Kageyama

Inna Chervoneva

Marlana Orloff

Ryan Weight

Michael J Mastrangelo

Massimo Cristofanilli

Takami Sato

Affiliations

Soon will be listed here.

Abstract

Background: CTCs provide prognostic information and their application is under investigation in multiple tumor types. Of the multiple variables inherent in any such process, none is more important to outcome than the appropriateness of the sample source. To address this question, we investigated CTCs in paired peripheral venous and arterial blood specimens obtained from stage IV uveal melanoma patients.

Methods: Blood specimens were obtained from both common femoral arteries and antecubital veins in 17 uveal melanoma patients with multiple hepatic metastases for CTC measurements.

Finding: CTCs were detectable with greater frequency (100%) and in larger numbers (median 5, range 1 to 168) in all arterial blood specimens than in venous samples (52.9%; median 1, range 0 to 8). Patients with hepatic as well as extra-hepatic metastasis showed higher number of arterial CTCs, compared to patients with liver-only metastasis (p = 0.003). There was no significant association between the number of arterial CTCs and the tumor burden within the liver in patients who had liver-only metastases.

Interpretation: Our data indicate that arterial blood specimens might be a better source of circulating uveal melanoma cells. Although less conveniently processed, perhaps arterial blood should be evaluated as sample source for measurement of CTCs.

Citing Articles

The Dynamic Landscape of the Coagulome of Metastatic Malignant Melanoma.

Arnault J, Chemmama K, Ferroudj K, Demagny J, Panicot-Dubois L, Galmiche A Int J Mol Sci. 2025; 26(4).

PMID: 40003901 PMC: 11855523. DOI: 10.3390/ijms26041435.

[Circulating tumor cells in uveal melanoma : "The needle in the haystack"].

Grisanti S, Sonntag S, Tura S Ophthalmologie. 2024; 121(12):954-962.

PMID: 39580374 DOI: 10.1007/s00347-024-02136-z.

Heterogeneity and molecular landscape of melanoma: implications for targeted therapy.

Beigi Y, Lanjanian H, Fayazi R, Salimi M, Hoseyni B, Noroozizadeh M Mol Biomed. 2024; 5(1):17.

PMID: 38724687 PMC: 11082128. DOI: 10.1186/s43556-024-00182-2.

Biopsy Techniques for Musculoskeletal Tumors: Basic Principles and Specialized Techniques.

Mavrogenis A, Altsitzioglou P, Tsukamoto S, Errani C Curr Oncol. 2024; 31(2):900-917.

PMID: 38392061 PMC: 10888002. DOI: 10.3390/curroncol31020067.

Peripheral arterial rather than venous blood is a better source of circulating tumor cells in early lung cancer.

Wang Z, Feng Y, Wang Y, Ma Y, Liu J, Li D Thorac Cancer. 2024; 15(8):654-660.

PMID: 38297462 PMC: 10928244. DOI: 10.1111/1759-7714.15236.

References

Budd G, Cristofanilli M, Ellis M, Stopeck A, Borden E, Miller M . Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006; 12(21):6403-9. DOI: 10.1158/1078-0432.CCR-05-1769. View

Kujala E, Makitie T, Kivela T . Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003; 44(11):4651-9. DOI: 10.1167/iovs.03-0538. View

Mehes G, Witt A, Kubista E, Ambros P . Circulating breast cancer cells are frequently apoptotic. Am J Pathol. 2001; 159(1):17-20. PMC: 1850424. DOI: 10.1016/S0002-9440(10)61667-7. View

Jiao L, Apostolopoulos C, Jacob J, Szydlo R, Johnson N, Tsim N . Unique localization of circulating tumor cells in patients with hepatic metastases. J Clin Oncol. 2009; 27(36):6160-5. DOI: 10.1200/JCO.2009.24.5837. View

Menyaev Y, Nedosekin D, Sarimollaoglu M, Juratli M, Galanzha E, Tuchin V . Optical clearing in photoacoustic flow cytometry. Biomed Opt Express. 2014; 4(12):3030-41. PMC: 3862168. DOI: 10.1364/BOE.4.003030. View

Fernandez S, Bingham C, Fittipaldi P, Austin L, Palazzo J, Palmer G . TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients. Breast Cancer Res. 2014; 16(5):445. PMC: 4303125. DOI: 10.1186/s13058-014-0445-3. View

Rao C, Bui T, Connelly M, Doyle G, Karydis I, Middleton M . Circulating melanoma cells and survival in metastatic melanoma. Int J Oncol. 2011; 38(3):755-60. DOI: 10.3892/ijo.2011.896. View

Cohen S, Punt C, Iannotti N, Saidman B, Sabbath K, Gabrail N . Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26(19):3213-21. DOI: 10.1200/JCO.2007.15.8923. View

Ewens K, Kanetsky P, Richards-Yutz J, Purrazzella J, Shields C, Ganguly T . Chromosome 3 status combined with BAP1 and EIF1AX mutation profiles are associated with metastasis in uveal melanoma. Invest Ophthalmol Vis Sci. 2014; 55(8):5160-7. DOI: 10.1167/iovs.14-14550. View

10.

Harbour J, Onken M, Roberson E, Duan S, Cao L, Worley L . Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010; 330(6009):1410-3. PMC: 3087380. DOI: 10.1126/science.1194472. View

11.

Yoshida M, Selvan S, McCue P, DeAngelis T, Baserga R, Fujii A . Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth. Pigment Cell Melanoma Res. 2013; 27(2):297-308. DOI: 10.1111/pcmr.12206. View

12.

Eskelin S, Pyrhonen S, Summanen P, Hahka-Kemppinen M, Kivela T . Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment. Ophthalmology. 2000; 107(8):1443-9. DOI: 10.1016/s0161-6420(00)00182-2. View

13.

Singh A, Shields C, Shields J . Prognostic factors in uveal melanoma. Melanoma Res. 2001; 11(3):255-63. DOI: 10.1097/00008390-200106000-00007. View

14.

Dong Y, Skelley A, Merdek K, Sprott K, Jiang C, Pierceall W . Microfluidics and circulating tumor cells. J Mol Diagn. 2012; 15(2):149-57. DOI: 10.1016/j.jmoldx.2012.09.004. View

15.

Mazzini C, Pinzani P, Salvianti F, Scatena C, Paglierani M, Ucci F . Circulating tumor cells detection and counting in uveal melanomas by a filtration-based method. Cancers (Basel). 2014; 6(1):323-32. PMC: 3980594. DOI: 10.3390/cancers6010323. View

16.

Chattopadhyay C, Grimm E, Woodman S . Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration. PLoS One. 2014; 9(2):e83957. PMC: 3923717. DOI: 10.1371/journal.pone.0083957. View

17.

Li H, Alizadeh H, Niederkorn J . Differential expression of chemokine receptors on uveal melanoma cells and their metastases. Invest Ophthalmol Vis Sci. 2008; 49(2):636-43. DOI: 10.1167/iovs.07-1035. View

18.

. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol. 2001; 119(5):670-6. DOI: 10.1001/archopht.119.5.670. View

19.

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

20.

Weissenstein U, Schumann A, Reif M, Link S, Toffol-Schmidt U, Heusser P . Detection of circulating tumor cells in blood of metastatic breast cancer patients using a combination of cytokeratin and EpCAM antibodies. BMC Cancer. 2012; 12:206. PMC: 3404911. DOI: 10.1186/1471-2407-12-206. View